Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Director/PDMR Shareholding

4 Jan 2022 09:27

RNS Number : 3367X
IQ-AI Limited
04 January 2022
Β 

4 January 2022

IQ-AI Ltd

("IQ-AI" or the "Company")

Β 

Director/PDMR Shareholding

Β 

IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company ("Ordinary Shares") at an exercise price of 5.88p per share. The option will vest on 15 December 2024.

Β 

Michael Schmainda is currently interested in 9,108,400 Ordinary Shares, representing 4.99 per cent. of the voting rights of the Company.

Β 

The Directors of the Company accept responsibility for the contents of this announcement

Β 

-ENDS-

Β 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

Β 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

Β 

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Schmainda

2

Reason for the notification

a)

Position/status

Director of the Company

b)

Initial notification /Amendment

Β 

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Limited

b)

LEI

213800SPW48XRJS2QH57

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

Β 

Β 

Β 

Β 

Β 

ISIN: JE00BD4H0R42

b)

Nature of the transaction

Grant of Option

Β 

c)

Price(s) and volume(s)

5,969,792 ordinary shares at 5.88p per share

Β 

d)

Aggregated information

- Aggregated volume

- Price

Β 

Β 

N/A (single transaction)

Β 

e)

Date of the transaction

15 December 2021

Β 

f)

Place of the transaction

N/A

Β 

Β 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHEANFLEADAEEA
Date   Source Headline
2nd Jan 201912:20 pmRNSHolding(s) in Company
13th Dec 20189:00 amRNSPrice Monitoring Extension
13th Dec 20187:00 amRNSStoneChecker 510k Update
11th Dec 20187:00 amRNSInstallation at Barrow Neurological Institute
28th Nov 20187:00 amRNSImaging Biometrics® Update
16th Nov 20187:00 amRNSFirst Commercial Sale of StoneChecker Software
22nd Oct 20187:00 amRNSIQ-AI files patent for Contrast-Free Imaging
4th Oct 20182:58 pmRNSResult of EGM and Change of Name
27th Sep 20187:00 amRNSIB announce agreement to develop a diagnostic tool
18th Sep 20187:00 amRNSProposed name change and notice of EGM
11th Sep 20189:00 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSHalf-year Report
6th Aug 20182:51 pmRNSHolding(s) in Company
6th Aug 20187:00 amRNSAppointment of CEO to the Operating Subsidiaries
1st Aug 20184:28 pmRNSPublication of a Prospectus
31st Jul 20183:54 pmRNSResult of AGM and GM
18th Jul 20181:24 pmRNSNon Regulatory - Vox Markets Podcast
18th Jul 20188:57 amRNSHolding(s) in Company
17th Jul 20187:00 amRNSECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB
16th Jul 20187:00 amRNSPlacing, Notice of AGM and GM
2nd Jul 20188:34 amRNSMedimsight and IB Enter into Partnership
13th Jun 20187:00 amRNSImaging Biometrics and QMENTA announce partnership
9th May 20187:00 amRNSIB Software Chosen by St. Savvas Oncology Hospital
30th Apr 20184:25 pmRNSFinal Results
11th Apr 20187:00 amRNSIMAGING BIOMETRICS ANNOUNCES PARTNERSHIP
29th Mar 20182:52 pmRNSTotal Voting Rights
13th Mar 201810:54 amRNSTotal Voting Rights
13th Mar 20187:40 amRNSAcquisition of Imaging Biometrics
6th Mar 20187:00 amRNSStoneChecker signs agreement with Korea ISG
8th Feb 20181:44 pmRNSPotential Acquisition
8th Feb 20189:05 amRNSSecond Price Monitoring Extn
8th Feb 20189:00 amRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSCE marked release of StoneChecker® Software
6th Nov 20174:40 pmRNSSecond Price Monitoring Extn
6th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSUpdate on Business Operations
9th Oct 20172:33 pmRNSHolding(s) in Company
18th Sep 20177:00 amRNSUpdate on Product Development and Warrant Exercise
4th Sep 20179:49 amRNSStone Checker Update
30th Aug 201710:04 amRNSHolding(s) in Company
17th Aug 20177:01 amRNSDirector Dealings
17th Aug 20177:00 amRNSHalf-year Report
14th Aug 201710:12 amRNSHolding(s) in Company
27th Jul 20174:40 pmRNSSecond Price Monitoring Extn
27th Jul 20174:35 pmRNSPrice Monitoring Extension
11th Jul 20177:00 amRNSUpdate on Operations
3rd Jul 20177:00 amRNSConversion of Convertible Loan Notes into Equity
27th Jun 20174:40 pmRNSSecond Price Monitoring Extn
27th Jun 20174:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.